Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

triamcinolone intravitreal (Rx)Brand and Other Names:Triesence, Trivaris Intravitreal

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable suspension, intravitreal (as acetonide salt)

  • 4mg/0.05mL
  • 4mg/0.1mL
more...

Ophthalmic Disease

Indicated for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to ophthalmic corticosteroids

Initial: 4 mg intravitreal

Visualization During Vitrectomy (Triesence)

1-4 mg intravitreal

Intravitreal Preparation

Trivaris Intravitreal

  • Available without an attached needle, therefore, it is necessary to firmly attach a desired needle to the syringe (27 gauge, 0.5-inch needle suggested)
  • Prepare the proper volume to be injected by advancing the plunger to the single line marked on the prefilled glass syringe shaft; hold the syringe and the needle at an angle and express excess gel suspension over a sterile surface
  • The plunger is correctly positioned when white compound is no longer visible between the plunger and the fill line on the syringe
  • This will provide the recommended dose of 4 mg/0.05 mL
  • Always check the needle to ensure it is firmly attached to the syringe before injecting the patient

Triesence

  • The vial should be vigorously shaken for 10 seconds before use to ensure a uniform suspension
  • Prior to withdrawal, the suspension should be inspected for clumping or granular appearance (agglomeration)
  • An agglomerated product results from exposure to freezing temperatures and should not be used
  • After withdrawal, inject without delay to prevent settling in the syringe

Intravitreal Administration

The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent)

Adequate anesthesia and a broad-spectrum antimicrobial should be administered prior to the injection

Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis

Each syringe should only be used for the treatment of a single eye

If the contralateral eye requires treatment, a new syringe should be used and the sterile field, syringe, gloves, drapes, and eyelid speculum and injection needles should be changed before administered to the other eye

Storage

Keep refrigerated 36-46 degrees F (2- 8 degrees C) until use

Avoid freezing and protect from light

Safety and efficacy not established

Next

Adverse Effects

Frequency Not Defined

Abnormal sensation in eye

Anterior chamber cells

Anterior chamber flare

Cataract

Cataract cortical

Cataract nuclear

Cataract subcapsular

Conjunctival hemorrhage

Exophthalmos

Eye irritation

Eye pain

Eye pruritus

Foreign body sensation in eyes

Glaucoma

Intraocular pressure increased

Injection site hemorrhage

Lacrimation increased

Vitreous detachment

Vitreous floaters

Rare instances of blindness associated with intravitreal or periocular injections

Previous
Next

Warnings

Contraindications

Hypersensitivity

Not for intravenous administration

Cautions

Prolonged use may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses

The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes

Intraocular pressure may become elevated in some individuals; if steroid therapy is continued for more than 6 weeks, IOP should be monitored

Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex because of possible corneal perforation; do NOT use in active ocular herpes simplex

Endophthalmitis: rate of infectious culture positive endophthalmitis is 0.5%; proper aseptic techniques should always be used when administering triamcinolone acetonide

In addition, patients should be monitored following the injection to permit early treatment should an infection occur

Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity

Previous
Next

Pregnancy & Lactation

Pregnancy Category: D

Lactation: Distributed in breast milk; caution advised

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Peak aqueous humor concentration: 2151-7202 ng/mL

AUC: 231-1911 ng•h/mL

Half-Life: 18.7 ± 5.7 days

Mechanism of Action

Glucocorticoid

Elicits anti-inflammatory effects; edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited

Depresses the production of eosinophils and lymphocytes

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.